劲方医药-B(02595)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02595 劲方医药-B

未开盘 04-28 16:08:26

42.780

-5.320

-11.06%

最高49.560	最低42.380	成交量338.75万
今开48.500	昨收48.100	日振幅14.93%
总市值158.29亿	流通市值144.60亿	总股本3.70亿
成交额1.50亿	换手率1.00%	流通股本3.38亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02595","market":"HK","secType":"STK","nameCN":"劲方医药-B","latestPrice":42.78,"timestamp":1777363706007,"preClose":48.1,"halted":0,"volume":3387546,"delay":0,"changeRate":-0.11060291060291061,"floatShares":338000000,"shares":370000000,"eps":-6.957704501821886,"marketStatus":"未开盘","change":-5.32,"latestTime":"04-28 16:08:26","open":48.5,"high":49.56,"low":42.38,"amount":149703307,"amplitude":0.149272,"askPrice":42.78,"askSize":1200,"bidPrice":42.76,"bidSize":400,"shortable":3,"etf":0,"ttmEps":-6.14845583983074,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777426200000},"marketStatusCode":0,"adr":0,"listingDate":1758211200000,"exchange":"SEHK","adjPreClose":48.1,"openAndCloseTimeList":[[1777339800000,1777348800000],[1777352400000,1777363200000]],"volumeRatio":2.193136040534496,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02595","defaultTab":"news","newsList":[{"id":"2630343326","title":"劲方医药-B(02595)：Rev Med发出函件所涉主体、产品、争议事项均与公司无关","url":"https://stock-news.laohu8.com/highlight/detail?id=2630343326","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630343326?lang=zh_cn&edition=full","pubTime":"2026-04-28 12:36","pubTimestamp":1777351016,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，公司近期注意到若干报导，涉及 Revolution Medicines Inc.(“RevMed”)向第三方公司发出有关RAS抑制剂专利及商业秘密争议的函件。公司特此澄清并强调：Rev Med发出函件所涉主体、产品、争议事项均与公司无关，劲方Pan RAS抑制剂GFH276具备完全独立、自主原创的知识产权，不存在类似侵权或商业秘密争议风险。劲方针对Pan RAS抑制剂项目已构建全面的全球专利布局，涵盖GFH276化合物结构的专利已于2025年3月6日正式公开，专利保护期预计可至2044年。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435107.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","02595","BK1161","159938","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185566851","title":"劲方医药宣布GFH276基于自主知识产权平台开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1185566851","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185566851?lang=zh_cn&edition=full","pubTime":"2026-04-28 12:31","pubTimestamp":1777350672,"startTime":"0","endTime":"0","summary":"劲方医药（上海）有限公司近日披露，其创新药物GFH276完全基于公司独立自主的知识产权体系研发完成。该候选药物从早期发现到临床前研究阶段，均依托企业自主研发的技术平台推进，体现了公司在原创药物开发领域的核心竞争优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186333823","title":"异动解读 | 澄清与Revmed函件无关，劲方医药-B盘中大跌11.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=1186333823","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186333823?lang=zh_cn&edition=full","pubTime":"2026-04-28 12:31","pubTimestamp":1777350670,"startTime":"0","endTime":"0","summary":"劲方医药-B今日盘中股价大幅下跌11.85%，引发了市场关注。消息面上，劲方医药（上海）股份有限公司发布声明，澄清Revmed往来函件中提及的所有实体、产品或争议事项均与本公司完全无关。市场分析认为，股价的剧烈波动可能与此前市场对公司可能卷入相关争议的担忧有关，公司的澄清声明旨在消除误解。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110941813","title":"劲方医药澄清：Revmed函件所涉主体、产品或争议事项均与公司无关","url":"https://stock-news.laohu8.com/highlight/detail?id=1110941813","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110941813?lang=zh_cn&edition=full","pubTime":"2026-04-28 12:30","pubTimestamp":1777350611,"startTime":"0","endTime":"0","summary":"劲方医药（上海）股份有限公司发布声明称，Revmed往来函件中提及的所有实体、产品或争议事项均与本公司完全无关。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629096870","title":"劲方医药-B午前涨超4% 公司公布泛RAS抑制剂GFH276临床前研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2629096870","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629096870?lang=zh_cn&edition=full","pubTime":"2026-04-22 11:54","pubTimestamp":1776830040,"startTime":"0","endTime":"0","summary":"　　劲方医药-B盘中涨近6%，截至发稿，股价上涨4.41%，现报45.94港元，成交额2121.73万港元。　　劲方医药宣布，公司自主开发的口服Pan RAS抑制剂GFH276临床前研究数据，于当地时间4月21日登陆美国癌症研究协会年会壁报展示。　　此外，GFH276与西妥昔单抗、化疗药物或PD-1单抗分别联用的动物实验中，可展现显著的抑瘤增效及无瘤生存期延长。据悉，GFH276为全球第三款进入临床试验的Pan RAS抑制剂，并在临床早期数据中显示契合临床前疗效及安全性的初步结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-04-22/doc-inhvixkk6243796.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09939","BK1515","02595","BK1161","BK1574","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163605522","title":"劲方医药-B（02595）2025年收入稳增 研发投入加码 资产负债表显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1163605522","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163605522?lang=zh_cn&edition=full","pubTime":"2026-04-17 22:54","pubTimestamp":1776437647,"startTime":"0","endTime":"0","summary":"根据年度报告披露，劲方医药-B在截至2025年12月31日止年度实现收入1.30亿元人民币，较2024年的1.05亿元增长24.4%。同期销售成本为46.61百万元人民币，其他收入及收益为34.81百万元人民币，研发成本则达到3.32亿元人民币，较上年的2.82亿元有所上升。综上所述，劲方医药-B在2025年度的收入与研发投入均有不同程度提升，核心产品管线稳步推进，资产负债表结构也显著改善。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199390862","title":"劲方医药-B拟回购最多10%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1199390862","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199390862?lang=zh_cn&edition=full","pubTime":"2026-04-17 22:51","pubTimestamp":1776437495,"startTime":"0","endTime":"0","summary":"劲方医药科技（上海）股份有限公司最新公告显示，该公司已获董事会批准一项股份购回授权，将最多回购不超过已发行股本的10%。截至本次公告基准日，公司已发行股份约3.70亿股，按此估算，此次购回规模最高可达约3703.67万股。若该授权在2026年5月11日的股东大会上获批，公司将在授权期间根据市场情况适时执行购回，并于适用法律及规则所允许的范围内对购回股份进行处理。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627406715","title":"国金证券：首次覆盖劲方医药-B(02595)给予“买入”评级 目标价为55.63港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627406715","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627406715?lang=zh_cn&edition=full","pubTime":"2026-04-15 14:48","pubTimestamp":1776235705,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国金证券发布研报称，预计劲方医药-B26/27/28年销售收入为1.46/1.60/3.35亿元，同比+12.3%/+9.4%/+109.1%，归母净利润为-1.85/-1.84/-2.36亿元。基于DCF模型估值，计算合理市值为179.7亿元，对应合理目标价为55.63港元/股。首次覆盖，给予“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428726.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","159938","02595","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627479216","title":"港股异动 | 创新药概念股上涨，劲方医药涨超9%！国办发文健全药价形成机制，花旗研报称创新药企有望受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2627479216","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627479216?lang=zh_cn&edition=full","pubTime":"2026-04-15 10:21","pubTimestamp":1776219660,"startTime":"0","endTime":"0","summary":"4月15日，创新药概念股上涨，$劲方医药-B$涨超9%，$信达生物$涨超4%，$恒瑞医药$、$石药集团$跟涨。重点创新药企/生物制药公司将成为受益者，如$恒瑞医药$、石药集团、信达生物以及其他跨国公司。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"91f24949debf4aed7e22faec526c7ddd","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428631.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"港股异动 | 创新药概念股上涨，劲方医药涨超9%！国办发文健全药价形成机制，花旗指恒瑞等创新药企有望受益","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0008368742.USD","LU0880133367.SGD","LU1813983027.USD","LU1969619763.USD","02595","IE00BZ08YR35.GBP","BK1574","LU1008478684.HKD","LU0648001328.SGD","BK4566","LU0072913022.USD","BK1521","IE00BZ08YS42.EUR","SG9999004220.SGD","LU2097828805.USD","LU2125154778.USD","LU2039709279.SGD","LU2097828714.EUR","LU2417539215.USD","LU0314106906.USD","LU0359201885.HKD","LU1152091754.HKD","LU0359201612.USD","LU0359202008.SGD","LU1244550494.USD","LU2097828557.USD","LU0098860793.USD","IE00BSNM7G36.USD","IE0008369823.USD","LU1807302812.USD","LU2097828631.EUR","LU2456880835.USD","LU2328871848.SGD","LU1226288253.USD","LU0315179316.USD","IE00B543WZ88.USD","LU1226287792.SGD","LU2462157665.USD","LU0128525689.USD","LU0314109678.HKD","BK4588","LU0980610538.SGD","BK4504","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627949947","title":"港股劲方医药-B盘中涨超22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627949947","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627949947?lang=zh_cn&edition=full","pubTime":"2026-04-14 12:01","pubTimestamp":1776139262,"startTime":"0","endTime":"0","summary":"【港股劲方医药-B盘中涨超22%】4月14日，劲方医药-B(02595.HK)盘中涨超22%，截至发稿涨14.37%，报44.88港元，成交额1.94亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604143704180475.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604143704180475.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["VXUS","02595","BK4585","159938","09939","BK4588","BK1515","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145482467","title":"劲方医药-B3月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1145482467","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145482467?lang=zh_cn&edition=full","pubTime":"2026-04-09 17:11","pubTimestamp":1775725900,"startTime":"0","endTime":"0","summary":"劲方医药科技（上海）股份有限公司（下称“劲方医药-B”）于2026年4月9日发布截至2026年3月31日的股份变动月报。公告显示，公司本月内未新增发行、未进行股份购回或注销，各项股本数据保持不变。\n根据公告，截至3月31日，公司已发行H股338,029,020股，未上市股份32,337,610股，合计370,366,630股，所有股份的每股面值为人民币0.1元，总股本面值为人民币37,036,663元，与上月保持一致。报告期内，公司无新增股份期权或股权激励计划相关活动，也无购回及注销股份情况。\n公司同时确认已遵守香港联合交易所有限公司相关上市规则及法律规定。该公告由公司联席公司秘书张巍签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626971565","title":"港股异动 | 劲方医药-B(02595)早盘涨超5% GFH375获得第二项突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2626971565","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626971565?lang=zh_cn&edition=full","pubTime":"2026-04-09 09:34","pubTimestamp":1775698443,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，劲方医药-B早盘涨超5%，截至发稿，涨4.55%，报37.2港元，成交额553.09万港元。消息面上，劲方医药发布公告，口服KRAS G12D 抑制剂GFH375已被国家药品监督管理局药品审评中心纳入突破性疗法认定名单，拟用于单药治疗至少接受过一种系统性治疗的KRAS G12D突变型转移性胰腺癌患者。GFH375/VS-7375的海外临床研究由劲方合作伙伴Verastem Oncology于去年在美国启动，VS-7375已获得美国FDA快速通道资格认定治疗一线及后线KRAS G12D突变型胰腺导管腺癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426340.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1574","02595","159938","BK1515","09939","BK1161","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626996975","title":"劲方医药-B(02595)：GFH375获得第二项突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2626996975","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626996975?lang=zh_cn&edition=full","pubTime":"2026-04-09 08:09","pubTimestamp":1775693389,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B 发布公告，口服KRAS G12D 抑制剂GFH375已被国家药品监督管理局药品审评中心纳入突破性疗法认定名单，拟用于单药治疗至少接受过一种系统性治疗的KRAS G12D突变型转移性胰腺癌患者。GFH375/VS-7375 的海外临床研究由劲方合作伙伴Verastem Oncology于2025年在美国启动，VS-7375已获得美国FDA快速通道资格认定治疗一线及后线KRAS G12D突变型胰腺导管腺癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426306.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1515","02595","BK1574","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172889689","title":"异动解读 | 劲方医药-B获Wellington Management增持，盘中大涨5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=1172889689","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172889689?lang=zh_cn&edition=full","pubTime":"2026-03-31 10:10","pubTimestamp":1774923054,"startTime":"0","endTime":"0","summary":"劲方医药-B今日盘中大涨5.14%，引起了市场的广泛关注。消息面上，劲方医药-B获得Wellington Management Group LLP增持约31.82万股，总金额约为982.60万港元，增持后持股比例达到7.02%。机构投资者的增持行为通常被视为对公司前景的积极信号，增强了市场信心。Wellington Management Group LLP作为知名投资机构，其增持动作可能反映了对劲方医药-B长期价值的认可，从而推动了股价的上涨。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623314171","title":"Wellington Management Group LLP增持劲方医药-B(02595)约31.82万股 每股均价约30.88港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2623314171","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623314171?lang=zh_cn&edition=full","pubTime":"2026-03-30 19:25","pubTimestamp":1774869941,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，3月26日，Wellington Management Group LLP增持劲方医药-B(02595)31.8247万股，每股均价30.8754港元，总金额约为982.60万港元。增持后最新持股数目约为2374.17万股，持股比例为7.02%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1515","EWH","159938","BK1161","09939","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622873168","title":"里昂：升劲方医药-B(02595)目标价至61.9港元 评级“跑赢大市”","url":"https://stock-news.laohu8.com/highlight/detail?id=2622873168","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622873168?lang=zh_cn&edition=full","pubTime":"2026-03-26 11:04","pubTimestamp":1774494280,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，里昂发布研报称，劲方医药-B(02595)去年收入人民币1.3亿元，同比增长24.42%;研发成本2.82亿元，同比减少15.01%;净亏损17.95亿元，同比扩大164.82%，均优于市场预期。G12D GFH375已进入胰脏癌注册试验阶段，而pan-RAS GFH276有望成为劲方医药的长期增长动力。GFH276的I期剂量递增试验中已观察到积极的安全性讯号。该行称，将公司今年和明年盈利预测上调4%及5.3%，其目标价由60.8港元上调至61.9港元，维持其评级为跑赢大市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419298.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","02595","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122554050","title":"异动解读 | 劲方医药-B盘中大涨5.34%，年度业绩增长及核心药物III期进展成催化剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1122554050","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122554050?lang=zh_cn&edition=full","pubTime":"2026-03-25 10:01","pubTimestamp":1774404060,"startTime":"0","endTime":"0","summary":"劲方医药-B今日盘中大涨5.34%，引起了市场的广泛关注。消息面上，公司发布了截至2025年12月31日止年度的年度业绩。公司收入达到1.3亿元人民币，同比增长约24.5%，增长主要得益于与Verastem就核心候选药物GFH375达成的合作及对外授权安排。其核心产品GFH375作为全球首个进入III期注册性临床试验的口服KRAS G12D抑制剂，已获得美国食品药品监督管理局的快速通道资格。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622014592","title":"劲方医药-B(02595)：黄美凤获委任为联席公司秘书","url":"https://stock-news.laohu8.com/highlight/detail?id=2622014592","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622014592?lang=zh_cn&edition=full","pubTime":"2026-03-25 07:52","pubTimestamp":1774396324,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，吴东澄因其专业事务重新安排及更深入参与客户业务及策略管理，已提呈辞任联席公司秘书、授权代表及法律程序文件代理人，自2026年3月24日起生效。黄美凤已获委任为联席公司秘书、授权代表及法律程序文件代理人，自2026年3月24日起生效。张巍将继续担任公司另一名联席公司秘书。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418439.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","02595","BK1574","09939","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622145900","title":"劲方医药-B(02595)发布年度业绩 净亏损17.95亿元 同比扩大164.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622145900","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622145900?lang=zh_cn&edition=full","pubTime":"2026-03-25 07:50","pubTimestamp":1774396243,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B 发布截至2025年12月31日止年度业绩，收入人民币1.3亿元，同比增长24.42%;研发成本2.82亿元，同比减少15.01%;净亏损17.95亿元，同比扩大164.82%。公司历年来达成多个国内外授权交易，营业收入保持稳健。2025年度营业收入超过1.3亿元人民币、同比增幅近25%。此外公司现金流储备充足，截至2025年底现金及银行结余超过20亿元人民币。同时本公司是唯一一家在上市时拥有已商业化的1类创新药并产生对外授权收入的上市规则第18A章上市公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418438.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","159938","09939","BK1161","BK1515","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621932770","title":"Wellington Management Group LLP增持劲方医药-B(02595)382.34万股 每股作价25.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621932770","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621932770?lang=zh_cn&edition=full","pubTime":"2026-03-23 19:07","pubTimestamp":1774264076,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，3月19日，Wellington Management Group LLP增持劲方医药-B(02595)382.34万股，每股作价25.5港元，总金额为9749.67万港元。增持后最新持股数目约为2159.22万股，持股比例为6.39%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417505.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","02595","BK1574","09939","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.genfleet.com","stockEarnings":[{"period":"1week","weight":-0.0277},{"period":"1month","weight":0.3115},{"period":"3month","weight":0.398},{"period":"6month","weight":0.6095},{"period":"1year","weight":1.0981},{"period":"ytd","weight":0.799}],"compareEarnings":[{"period":"1week","weight":-0.0305},{"period":"1month","weight":0.0292},{"period":"3month","weight":-0.0772},{"period":"6month","weight":-0.0229},{"period":"1year","weight":0.1688},{"period":"ytd","weight":0.0019}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"劲方医药科技（上海）有限公司是一家专注于创新药物研发的中国公司。该公司为肿瘤、自身免疫性疾病和炎症性疾病提供有效的新型治疗方案。该公司的研发平台涵盖靶点发现、分子发现与评估、转化科学和临床开发，以及制剂研究、工艺开发和质量分析等关键化学生产和控制环节。该公司主要致力于新分子类型和新药物模式的开发，分子工艺路线和质量标准的研究，以及差异化临床开发策略和路径的探索。该公司主要在中国国内和海外市场开展业务。","exchange":"SEHK","name":"劲方医药-B","nameEN":"GENFLEET-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"劲方医药-B(02595)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供劲方医药-B(02595)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"劲方医药-B,02595,劲方医药-B股票,劲方医药-B股票老虎,劲方医药-B股票老虎国际,劲方医药-B行情,劲方医药-B股票行情,劲方医药-B股价,劲方医药-B股市,劲方医药-B股票价格,劲方医药-B股票交易,劲方医药-B股票购买,劲方医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"劲方医药-B(02595)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供劲方医药-B(02595)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}